Dave Ricks, Eli Lilly
Eli Lilly bets on an RNA base editing outfit leveraging the body's own enzymes to reverse mutations
With its controversial Alzheimer’s med donanemab nearly ready for FDA scrutiny, Eli Lilly has grown more emboldened in its efforts to become the top dog …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
